ARRY 382

Drug Profile

ARRY 382

Alternative Names: ARRY-382

Latest Information Update: 22 Aug 2016

Price : $50

At a glance

  • Originator Array BioPharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Macrophage colony stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Phase I Cancer

Most Recent Events

  • 04 Aug 2016 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease) in USA (PO)
  • 17 Mar 2016 Phase I development is ongoing in USA
  • 15 Mar 2011 Phase-I clinical trials in Cancer (Metastatic disease) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top